The U.S. Food and Drug Administration (FDA) has taken a significant step toward accelerating access to innovative medical devices for Medicare patients by selecting Dexcom as the first participant in its Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot program. This initiative marks a departure from traditional regulatory pathways, allowing manufacturers to offer unapproved devices to Medicare beneficiaries under specific conditions.
Enforcement Discretion as a Regulatory Tool
The TEMPO program operates through a mechanism called enforcement discretion, which permits the FDA to refrain from taking enforcement action against a device that hasn’t yet received full approval for a particular use. In this case, Dexcom’s continuous glucose monitoring (CGM) system will be made available to Medicare patients before formal approval, provided that the company meets certain criteria and demonstrates patient safety and effectiveness.
Implications for Digital Health Innovation
This move reflects the FDA’s growing recognition of the need for faster access to digital health solutions, especially as aging populations increasingly rely on technology to manage chronic conditions like diabetes. Dexcom, a leader in CGM technology, is well-positioned to provide valuable real-world data that could inform future regulatory decisions. The agency hopes that by allowing early access through TEMPO, it can better evaluate how new devices perform in actual clinical settings, potentially speeding up the approval process for similar products.
The program also underscores a broader shift in regulatory thinking, where agencies are exploring more flexible frameworks to keep pace with rapid technological advancements. While this approach introduces some risk, it could significantly benefit Medicare patients who may otherwise wait years for access to life-enhancing innovations.
Looking Ahead
With Dexcom as the pilot’s first participant, the FDA will closely monitor outcomes to assess the program’s effectiveness. If successful, TEMPO could pave the way for more companies to gain early access to Medicare patients, ultimately transforming how digital health innovations reach those who need them most.
